Owlstone Medical, a subsidiary of Owlstone, raised $58m in an oversubscribed funding round to continue development of its breath biopsy technology.
The series D round, announced 7 September, raised $8m more than its initial target, bringing the total amount raised
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?